{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:01:56Z","timestamp":1776276116461,"version":"3.50.1"},"reference-count":29,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.5582\/bst.2025.01178","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:07:23Z","timestamp":1752617243000},"page":"421-431","source":"Crossref","is-referenced-by-count":2,"title":["Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA"],"prefix":"10.5582","volume":"19","author":[{"given":"Bo","family":"Sun","sequence":"first","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"The Second Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Han","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuren","family":"Xia","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Clinical laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Ma","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Tian","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Endoscopy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin&apos;s Clinical Research Center for Cancer, Tianjin, China."},{"name":"Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Beaufr\u00e8re A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol. 2021; 74:1212-1224.","DOI":"10.1016\/j.jhep.2021.01.035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Calderaro J, Ghaffari Laleh N, Zeng Q, <i>et al<\/i>. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nat Commun. 2023; 14:8290.","DOI":"10.1038\/s41467-023-43749-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021; 21:541-557.","DOI":"10.1038\/s41568-021-00383-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Xue R, Chen L, Zhang C, <i>et al<\/i>. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell. 2019; 35:932-947.e938.","DOI":"10.1016\/j.ccell.2019.04.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nguyen CT, Caruso S, Maille P, <i>et al<\/i>. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. Clin Cancer Res. 2022; 28:540-551.","DOI":"10.1158\/1078-0432.CCR-21-1219"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Harding JJ, Khalil DN, Fabris L, Abou-Alfa GK. Rational development of combination therapies for biliary tract cancers. J Hepatol. 2023; 78:217-228.","DOI":"10.1016\/j.jhep.2022.09.004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gong W, Zhang S, Tian X, Chen W, He Y, Chen L, Ding T, Ren P, Shi L, Wu Q, Sun Y, Chen L, Guo H. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma. Hepatol Int. 2024; 18:1310-1325.","DOI":"10.1007\/s12072-024-10694-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chen X, Dong L, Chen L, <i>et al<\/i>. Epigenome-wide development and validation of a prognostic methylation score in intrahepatic cholangiocarcinoma based on machine learning strategies. Hepatobiliary Surg Nutr. 2023; 12:478-494.","DOI":"10.21037\/hbsn-21-424"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen L, Yin G, Wang Z, Liu Z, Sui C, Chen K, Song T, Xu W, Qi L, Li X. A predictive radiotranscriptomics model based on DCE-MRI for tumor immune landscape and immunotherapy in cholangiocarcinoma. Biosci Trends. 2024; 18:263-276.","DOI":"10.5582\/bst.2024.01121"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yang S, Qian L, Li Z, <i>et al<\/i>. Integrated Multi-Omics Landscape of Liver Metastases. Gastroenterology. 2023; 164:407-423.e417.","DOI":"10.1053\/j.gastro.2022.11.029"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dar FS, Abbas Z, Ahmed I, <i>et al<\/i>. National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma. World J Gastroenterol. 2024; 30:1018-1042.","DOI":"10.3748\/wjg.v30.i9.1018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ye L, Schneider JS, Ben Khaled N, Schirmacher P, Seifert C, Frey L, He Y, Geier A, De Toni EN, Zhang C, Reiter FP. Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management. Liver Cancer. 2024; 13:6-28.","DOI":"10.1159\/000530700"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jeong H, Kim KP, Jeong JH, Hwang DW, Lee JH, Kim KH, Moon DB, Lee MA, Park SJ, Chon HJ, Park JH, Lee JS, Ryoo BY, Yoo C. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology. 2023; 77:1540-1549.","DOI":"10.1097\/HEP.0000000000000046"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer. 2021; 7:606-623.","DOI":"10.1016\/j.trecan.2021.01.012"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Trikalinos NA, Zhou A, Doyle MBM, Fowler KJ, Morton A, Vachharajani N, Amin M, Keller JW, Chapman WC, Brunt EM, Tan BR. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw. 2018; 16:1193-1199.","DOI":"10.6004\/jnccn.2018.7053"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kataoka K, Mori K, Nakamura Y, <i>et al<\/i>. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol. 2024; 35:1015-1025.","DOI":"10.1016\/j.annonc.2024.08.2240"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023; 73:198-222.","DOI":"10.3322\/caac.21759"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Stoop TF, Sugawara T, Oba A, <i>et al<\/i>. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. JAMA Oncol. 2025; 11:276-287.","DOI":"10.1001\/jamaoncol.2024.5917"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. He GQ, Li Q, Jing XY, Li J, Gao J, Guo X. Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion. Mol Cancer. 2024; 23:269.","DOI":"10.1186\/s12943-024-02190-w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Rosenberg N, Van Haele M, Lanton T, <i>et al<\/i>. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2022; 77:1631-1641.","DOI":"10.1016\/j.jhep.2022.07.029"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023; 8:760-770.","DOI":"10.1016\/S2468-1253(23)00147-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gan X, Dong W, You W, Ding D, Yang Y, Sun D, Li W, Ding W, Liang Y, Yang F, Zhou W, Dong H, Yuan S. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma. Cancer Lett. 2024; 581:216513.","DOI":"10.1016\/j.canlet.2023.216513"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Calderaro J, Di Tommaso L, Maill\u00e9 P, <i>et al<\/i>. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol. 2022; 77:1586-1597.","DOI":"10.1016\/j.jhep.2022.07.019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Heng Q, Hou M, Leng Y, Yu H. Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma. Sci Rep. 2025; 15:16726.","DOI":"10.1038\/s41598-025-01817-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Heinze G, Wallisch C, Dunkler D. Variable selection \u2012 A review and recommendations for the practicing statistician. Biom J. 2018; 60:431-449.","DOI":"10.1002\/bimj.201700067"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Claasen M, Ivanics T, Beumer BR, de Wilde RF, Polak WG, Sapisochin G, JNM IJ. An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma(\u2730). JHEP Rep. 2023; 5:100745.","DOI":"10.1016\/j.jhepr.2023.100745"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kelley RK, Rimassa L, Cheng AL, <i>et al<\/i>. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23:995-1008.","DOI":"10.1016\/S1470-2045(22)00326-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yang H, Cheng J, Zhuang H, <i>et al<\/i>. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell. 2024; 42:535-551.e538.","DOI":"10.1016\/j.ccell.2024.03.004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Liu Q, Zhang X, Qi J, <i>et al<\/i>. Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC. Hepatology. 2025; 81:1164-1180.","DOI":"10.1097\/HEP.0000000000000962"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/4\/19_2025.01178\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:25:15Z","timestamp":1758342315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/4\/19_2025.01178\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01178","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"article-number":"2025.01178"}}